A hit and a miss with pegcetacoplan in late-stage trials leaves Apellis with shrinking prospects.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
Key catalysts approach for Orphazyme, Gemini and Immutep.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.